- 12 Jan 2018 Kymab ‘top European biotech to watch’ in 2018
- 4 Dec 2017 Anti-PD-L1 antibody KY1003 shows anti-tumour efficacy
- 17 Nov 2017 Kymab makes UK Fast 50 for growth
- 8 Nov 2017 KY1044 strongly inhibits tumour growth in models
- 21 Sep 2017 KY1005 impressive in acute GVHD model
- 31 Jul 2017 Kymab's KY1005 antibody in clinical trial
- 29 Jul 2017 Allan Bradley at Canaccord Genuity Growth Conference
- 16 Jun 2017 Kymab appoints Dr Martin Nicklasson as Non-Executive Chair
- 9 May 2017 Sonia Quaratino appointed Kymab CMO
- 23 Jan 2017 Arndt Schottelius appointed Executive VP R&D